Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Adult hepatocellular carcinoma is the most common primary liver cancer of adulthood. Derived from well-differentiated hepatocytes, it often develops from chronic liver cirrhosis which is most often due to hepatitis B and C virus or alcohol abuse. Symptoms are hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure.
Biomarker and diagnostic research for adult hepatocellular carcinoma has been reported in the published literature.
1 clinical trial registered. Interventions under study include other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE1. Research is primarily sponsored by academic and government institutions.
220 publications have been identified in PubMed for adult hepatocellular carcinoma. Research spans Basic Science / Preclinical (26%), Epidemiology / Natural History (19%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 55 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:35 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Disease patterns and progression | 41 | 19% |
Research summaries | 36 | 17% |
Testing and diagnosis research | 34 | 16% |
Clinical study results | 27 | 13% |
New treatment approaches | 14 | 7% |
Patient case studies | 5 | 2% |
Other research | 3 | 1% |
Budiman D (2026). [PMID: 41986186](https://pubmed.ncbi.nlm.nih.gov/41986186/). *Transplant Proc*. [Review / Meta-Analysis]
Chou TS (2026). [PMID: 41526898](https://pubmed.ncbi.nlm.nih.gov/41526898/). *BMC Med*. [Epidemiology / Natural History]
S Jabir M (2026). [PMID: 40960518](https://pubmed.ncbi.nlm.nih.gov/40960518/). *Naunyn-Schmiedeberg's archives of pharmacology*. [Basic Science / Preclinical]
Engin ED (2026). [PMID: 41972361](https://pubmed.ncbi.nlm.nih.gov/41972361/). *J Gastroenterol Hepatol*. [Review / Meta-Analysis]
Guttula PK (2026). [PMID: 42146432](https://pubmed.ncbi.nlm.nih.gov/42146432/). *bioRxiv*. [Basic Science / Preclinical]
El-Kholy O (2026). [PMID: 41759482](https://pubmed.ncbi.nlm.nih.gov/41759482/). *Curr Res Transl Med*. [Review / Meta-Analysis]
Imani A (2026). [PMID: 42118408](https://pubmed.ncbi.nlm.nih.gov/42118408/). *Clin Exp Med*. [Review / Meta-Analysis]
Torbenson M (2026). [PMID: 41804058](https://pubmed.ncbi.nlm.nih.gov/41804058/). *Am J Surg Pathol*. [Clinical Trial Publication]
Verma M (2026). [PMID: 41841669](https://pubmed.ncbi.nlm.nih.gov/41841669/). *Curr Opin Gastroenterol*. [Review / Meta-Analysis]
Ying S (2026). [PMID: 41883040](https://pubmed.ncbi.nlm.nih.gov/41883040/). *Aliment Pharmacol Ther*. [Other]